| Literature DB >> 26945987 |
Agete Tadewos Hirigo1, Demo Yemane Tesfaye2.
Abstract
BACKGROUND: Data regarding the influences of gender in metabolic syndrome (MetS) among patients using antiretroviral treatment (ART) in Ethiopia is scarce. The aim of this study was to assess the influences of gender in MetS and its components among HIV-infected patients receiving ART.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26945987 PMCID: PMC4779577 DOI: 10.1186/s13104-016-1953-2
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Characteristics of HIV infected patients using ART with gender category at Hawassa, Southern Ethiopia
| Variables | Males | Females |
|---|---|---|
| Age (years), median (IQR) | 35 (28.2–40.0) | 30 (25–35) |
| <25 | 8 (11.8) | 32 (27.4) |
| 26–35 | 27 (39.7) | 61 (52.1) |
| 36–45 | 26 (38.2) | 21 (17.9) |
| ≥46 | 7 (10.3) | 3 (2.6) |
| Marital status | ||
| Single | 15 (22.0) | 24 (20.5) |
| Married | 38 (55.9) | 54 (46.1) |
| Divorced | 7 (10.3) | 12 (10.2) |
| Widowed | 8 (11.7) | 27 (23.1) |
| Work status | ||
| Unemployed | 6 (8.8) | 14 (11.9) |
| Government | 16 (23.5) | 14 (11.9) |
| Private | 43 (63.2) | 53 (25.6) |
| Student | 3 (4.4) | 6 (5.1) |
| A housewife | – | 30 (29.0) |
| Physical exercise | ||
| Sedentary | 25 (36.7) | 57 (48.7) |
| Moderate | 38 (55.9) | 59 (50.4) |
| Vigorous | 5 (7.3) | 1 (0.8) |
| BMI (kg/m2) | 22.2 (3.2) | 22.2 (3.7) |
| <18.5 | 4 (5.9) | 21 (17.9) |
| 18.5–24.9 | 50 (73.5) | 75 (64.1) |
| ≥25 | 14 (20.6) | 21 (17.9) |
| CD4, cells/µl, median (IQR) | 340 (200–486) | 433 (326–572) |
| <200 | 14 (20.6) | 10 (8.5) |
| 200–400 | 25 (36.7) | 32 (27.4) |
| ≥400 | 29 (42.7) | 75 (64.1) |
| WHO clinical stage | ||
| I | 21 (30.9) | 37 (31.6) |
| II | 13 (19.1) | 21 (17.9) |
| III | 29 (42.6) | 48 (41.0) |
| IV | 5 (7.3) | 11 (9.4) |
| NRTIs | ||
| AZT | 21 (30.9) | 52 (44.4) |
| TDF | 27 (39.7) | 32 (27.3) |
| d4T | 20 (29.4) | 33 (28.2) |
| NNRTIs | ||
| EFV | 46 (67.6) | 63 (53.8) |
| NVP | 22 (32.3) | 54 (46.1) |
| ART duration (months) | 41.4 (19.4) | 45.1 (21.5) |
Values are the number (percent) for variables unless otherwise indicated
WHO world health organization, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non nucleoside reverse transcriptase inhibitor, BMI body mass index, ART antiretroviral therapy, AZT Zidovudine, EFV Efavirenz, NVP Nevirapine, IQR interquartile range
Gender based prevalence of parameters in HIV infected patients using ART at Hawassa, Southern Ethiopia
| Parameters | Males | Females |
|
|---|---|---|---|
| n = 68 | n = 117 | ||
| Total cholesterol | 188 (49.4) | 201 (50.2) |
|
| <200 mg/dl, n (%) | 43 (63.2) | 64 (54.7) | |
| ≥200 mg/dl | 25 (36.8) | 53 (45.3) |
|
| HDL-cholesterol | 42.1 (10.3) | 51.1 (31.9) | < |
| LDL-cholesterol | 108 (37.7) | 115 (42.4) |
|
| <130 mg/dl, n (%) | 46 (67.6) | 82 (70.0) | |
| ≥130 mg/dl, n (%) | 22 (32.3) | 35 (30.0) |
|
| Triglycerides | 196 (104.2) | 156 (98.5) |
|
| FBG | 98.6 (15) | 92.7 (17) |
|
| TC/HDL-c ratio | 4.6 (1.3) | 4.3 (1.2) |
|
| <5, n (%) | 42 (61.7) | 93 (79.5) | |
| ≥5, n (%) | 26 (38.2) | 24 (20.5) |
|
| WC | 87.7 (10) | 84 (9) |
|
| SBP | 113.1 (14.2) | 111.3 (16.5) |
|
| DBP | 73.9 (9.7) | 71.9 (10.1) |
|
Values are the Mean ± SD for continuous variables unless and otherwise indicated
SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, LDL-c low- density lipoprotein cholesterol, TG triglyceride, FBG fast blood glucose, SD standard deviation, WC waist circumference
Pattern of MetS and its components in gender among HIV infected patients using ART at Hawassa, southern Ethiopia
| Parameters | Males | Females | p value |
|---|---|---|---|
| SBP ≥130 mmHg | 9 (13.2) | 13 (11.1) | 0.66 |
| DBP >85 mmHg | 7 (10.3) | 15 (12.8) | 0.63 |
| FBG (NCEP-ATP criteria) ≥110 mg/dl | 14 (20.6) | 13 (11.1) | 0.07 |
| FBG (IDF criteria) ≥100 mg/dl | 29 (42.6) | 29 (24.8) |
|
| Hypertensive (≥130/85 mmHg) | 7 (10.3) | 11 (9.4) | 0.84 |
| TG ≥150 mg/dl | 39 (57.3) | 44 (37.6) |
|
| Low HDL-c (<40 mg/dl in males and <50 in females) | 39 (57.3) | 91 (77.8) |
|
| WC (IDF criteria) ≥94 cm in males and ≥80 cm in females | 13 (19.1) | 82 (70.1) | < |
| WC (NCEP criteria) ≥102 cm in males and ≥88 cm in females | 4 (5.9) | 38 (32.5) | < |
| MetS (IDF criteria) | 6 (8.8) | 39 (33.3) | < |
| MetS (NCEP-ATP criteria) | 12 (17.6) | 21 (17.9) | 0.95 |
Association of independent factors with metabolic syndrome among HIV infected patients using ART at Hawassa, southern Ethiopia
| Explanatory variable | Metabolic syndrome by using IDF criteria | Metabolic syndrome by using NCEP-ATP criteria | ||||
|---|---|---|---|---|---|---|
| Presence of MetS = N (%) | COR (95 % CI) | AOR (95 % CI) | Presence of MetS = N (%) | COR (95 % CI) | AOR (95 % CI) | |
| BMI (kg/m2) | ||||||
| ≤25 | 30 (16.2) | 1.00 | 1.00 | 21 (11.3) | 1.00 | 1.00 |
| >25 | 15 (8.1) | 3.0 (1.3–6.5) | 3.8 (1.5–9.8) | 12 (6.5) | 3.2 (1.4–7.4) | 3.4 (1.3–9.2) |
| p value |
|
|
|
| ||
| Gender | ||||||
| Male | 6 (3.2) | 1.00 | 1.00 | 12 (6.5) | 1.00 | 1.00 |
| Female | 39 (21.1) | 5.1 (2.0–12.9) | 7.9 (2.6–24.1) | 21 (11.3) | 1.0 (0.47–2.3) | 1.5 (0.24–1.8) |
| p value | < | < | 0.19 | 0.43 | ||
| Age (years) | ||||||
| ≤40 | 41 (22.1) | 1.00 | 1.00 | 25 (13.5) | 1.00 | 1.00 |
| >40 | 4 (2.1) | 0.66 (0.21–2.0) | 2.0 (0.45–9.5) | 8 (4.3) | 3.1 (1.2–8.3) | 3.8 (1.0–13.7) |
| p value | 0.21 | 0.35 |
|
| ||
| ART use (months) | ||||||
| ≤48 | 22 (11.9) | 1.00 | 1.00 | 20 (10.8) | 1.00 | 1.00 |
| >48 | 23 (12.4) | 1.8 (0.95–3.7) | 2.3 (1.0–5.4) | 13 (7.0) | 0.99 (0.46–2.1) | 0.8 (0.32–1.9) |
| p value | 0.07 |
| 0.20 | 0.33 | ||
| Cigarette | ||||||
| Never smoke | 43 (23.2) | 1.00 | 1.00 | 28 (15.1) | 1.00 | 1.00 |
| Still smoking | 2 (1.1) | 0.26 (0.06–1.1) | 0.17 (0.03–1.0) | 5 (2.7) | 1.3 (0.45–3.9) | 0.47 (0.10–2.1) |
| p value | 0.08 | 0.05 | 0.18 | 0.33 | ||
| Education | ||||||
| Illiterate | 1 (0.5) | 1.00 | 1.00 | 3 (1.6) | 1.00 | 1.00 |
| Primary | 22 (11.9) | 6.7 (0.8–53.3) | 10.1 (1.1–94) | 15 (8.1) | 1.2 (0.31–4.7) | 0.85 (0.17–4.3) |
| p value | 0.07 |
| 0.16 | 0.24 | ||
| Secondary and above | 22 (11.9) | 6.2 (0.79–49.9) | 10.9 (1.1–104) | 15 (8.1) | 1.1 (0.3–4.4) | 1.1 (0.45–2.8) |
| p value | 0.08 |
| 0.21 | 0.37 | ||
ART antiretroviral therapy, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, BMI body mass index, EFV Efavirenz, NVP Nevirapine, NNRTI non nucleoside reverse transcriptase inhibitors